Trials / Unknown
UnknownNCT04817306
Pan-canceR Early DetectIon projeCT (PREDICT)
A Prospective, Multicenter Study on Development and Validation of the Performance of a cfDNA Methylation-based Model for Early Cancer Detection (Pan-canceR Early DetectIon projeCT, PREDICT Study)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 14,026 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
PREDICT is a prospective, multicenter study for the early detection of pan-cancer through cell-free DNA (cfDNA) methylation-based model, in which approximately 14,000 participants will be enrolled. The development and validation of the model will be conducted in participants with cancers or benign diseases, along with non-tumor (healthy) individuals through a two-stage approach. The sensitivity and specificity of the model in cancer early detection will be evaluated, and the accuracy of the identification for tissue of origin will be obtained.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Multi-cancer early detection test | Blood collection and multi-cancer early detection testing |
Timeline
- Start date
- 2021-03-29
- Primary completion
- 2022-12-31
- Completion
- 2023-03-31
- First posted
- 2021-03-26
- Last updated
- 2021-03-30
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04817306. Inclusion in this directory is not an endorsement.